Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRISNASDAQ:CYTXNASDAQ:FBIONASDAQ:SABS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRISCuris$1.84+5.1%$2.19$1.02▼$8.29$18.94M3.680,098 shs131,473 shsCYTXCytori Therapeutics$0.30-3.5%$0.20$0.20▼$0.75$6.57M1.96915,302 shs4.14 million shsFBIOFortress Biotech$1.91+4.3%$1.82$1.33▼$2.89$55.59M1.75412,266 shs180,983 shsSABSSAB Biotherapeutics$1.73-1.1%$1.79$1.00▼$5.01$15.98M0.5267,087 shs14,060 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRISCuris0.00%-15.21%-23.01%+49.59%-70.56%CYTXCytori Therapeutics0.00%-5.93%-15.96%-61.75%-80.63%FBIOFortress Biotech0.00%+4.89%+1.54%+25.59%+8.47%SABSSAB Biotherapeutics0.00%+2.37%-4.95%+53.10%-40.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRISCuris2.8876 of 5 stars3.55.00.00.02.30.00.6CYTXCytori TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AFBIOFortress Biotech2.149 of 5 stars3.51.00.00.00.63.30.6SABSSAB Biotherapeutics3.0594 of 5 stars3.55.00.00.00.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRISCuris 3.00Buy$17.00823.91% UpsideCYTXCytori Therapeutics 0.00N/AN/AN/AFBIOFortress Biotech 3.00Buy$21.001,000.05% UpsideSABSSAB Biotherapeutics 3.00Buy$13.25665.90% UpsideCurrent Analyst Ratings BreakdownLatest CYTX, FBIO, CRIS, and SABS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025CRISCurisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$17.005/15/2025SABSSAB BiotherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/14/2025SABSSAB BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRISCuris$10.91M1.76N/AN/A($0.71) per share-2.59CYTXCytori Therapeutics$3.67M1.79N/AN/A$0.35 per share0.85FBIOFortress Biotech$57.67M0.98N/AN/A($0.06) per share-31.82SABSSAB Biotherapeutics$1.32M12.18N/AN/A$2.81 per share0.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRISCuris-$43.39M-$6.23N/AN/AN/A-376.08%N/A-97.14%7/30/2025 (Estimated)CYTXCytori Therapeutics-$12.63MN/A0.00∞N/A-242.60%-272.70%-56.23%N/AFBIOFortress Biotech-$46M-$2.23N/AN/AN/A-71.24%-4,712.53%-27.67%8/12/2025 (Estimated)SABSSAB Biotherapeutics-$34.10M-$3.70N/AN/AN/AN/A-105.14%-69.24%8/6/2025 (Estimated)Latest CYTX, FBIO, CRIS, and SABS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025SABSSAB Biotherapeutics-$1.00-$0.56+$0.44-$0.56$0.13 millionN/A5/6/2025Q1 2025CRISCuris-$1.14-$1.25-$0.11-$1.25$2.37 million$2.38 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRISCurisN/AN/AN/AN/AN/ACYTXCytori TherapeuticsN/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/ASABSSAB BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRISCurisN/A1.231.23CYTXCytori Therapeutics0.390.460.30FBIOFortress Biotech1.741.721.55SABSSAB Biotherapeutics0.151.691.69Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRISCuris29.97%CYTXCytori Therapeutics2.62%FBIOFortress Biotech96.51%SABSSAB Biotherapeutics7.82%Insider OwnershipCompanyInsider OwnershipCRISCuris5.45%CYTXCytori Therapeutics0.66%FBIOFortress Biotech27.90%SABSSAB Biotherapeutics27.77%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRISCuris6010.46 million9.89 millionNo DataCYTXCytori Therapeutics3722.16 millionN/ANot OptionableFBIOFortress Biotech17029.57 million21.32 millionOptionableSABSSAB Biotherapeutics1409.29 million6.71 millionNot OptionableCYTX, FBIO, CRIS, and SABS HeadlinesRecent News About These CompaniesSABS - SAB Biotherapeutics Inc Chart - MorningstarJuly 4 at 7:57 PM | morningstar.comMSAB Biotherapeutics, Inc.: SAB BIO Announces Q1 2025 Financial Results and Provides Company UpdatesMay 9, 2025 | finanznachrichten.deSAB BIO Announces Q1 2025 Financial Results and Provides Company UpdatesMay 9, 2025 | globenewswire.comCraig-Hallum Reaffirms Their Buy Rating on SAB Biotherapeutics (SABS)April 3, 2025 | markets.businessinsider.comSAB Biotherapeutics, Inc.: SAB BIO Reports Full Year 2024 Operating and Financial ResultsApril 2, 2025 | finanznachrichten.deSAB Biotherapeutics price target lowered to $20 from $25 at ChardanApril 2, 2025 | markets.businessinsider.comSAB Biotherapeutics held cash and equivalents of $20.8 million at end of 2024March 31, 2025 | markets.businessinsider.comSAB BIO Reports Full Year 2024 Operating and Financial ResultsMarch 31, 2025 | globenewswire.comSAB BIO to Participate in Upcoming Investor ConferencesJanuary 31, 2025 | globenewswire.comStrong Buy Recommendation for SAB-142: Promising Phase 1 Results and Future Market Potential in T1D TreatmentJanuary 29, 2025 | markets.businessinsider.comSAB Biotherapeutics, Inc.: SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142January 29, 2025 | finanznachrichten.deSAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142January 28, 2025 | globenewswire.comSAB Biotherapeutics (SABS) Gets a Buy from Craig-HallumJanuary 24, 2025 | markets.businessinsider.comSAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D TherapyJanuary 23, 2025 | globenewswire.comHere’s Why SAB Biotherapeutics, Inc. (NASDAQ:SABS) Is Among the Best Diabetes Stocks to Buy Under $10January 6, 2025 | insidermonkey.comSAB Biotherapeutics Leads The Pack Of 3 US Penny Stocks To ConsiderDecember 23, 2024 | finance.yahoo.comSAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023)November 9, 2024 | finance.yahoo.comPromising Outlook for SAB Biotherapeutics’ SAB-142 in Type 1 Diabetes Treatment Drives Buy RatingNovember 7, 2024 | markets.businessinsider.comSAB BIO Announces Third Quarter 2024 Financial Results and Provides Company UpdateNovember 6, 2024 | globenewswire.comCraig-Hallum Remains a Buy on SAB Biotherapeutics (SABS)October 15, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeThe Ultimate Trump Bump: These Gov't Backed Stocks Are ExplodingBy Leo Miller | July 2, 2025View The Ultimate Trump Bump: These Gov't Backed Stocks Are ExplodingCYTX, FBIO, CRIS, and SABS Company DescriptionsCuris NASDAQ:CRIS$1.84 +0.09 (+5.14%) Closing price 07/3/2025 01:59 PM EasternExtended Trading$1.78 -0.06 (-2.99%) As of 07/3/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.Cytori Therapeutics NASDAQ:CYTXCytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.Fortress Biotech NASDAQ:FBIO$1.91 +0.08 (+4.32%) As of 07/3/2025 03:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.SAB Biotherapeutics NASDAQ:SABS$1.73 -0.02 (-1.14%) As of 07/3/2025 02:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
